Article Text
PDF
Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
Q What is the safety and efficacy of atypical antipsychotic medications in outpatients with Alzheimer’s disease?
METHODS
Design:
Randomised controlled trial.
Allocation:
Unclear.
Blinding:
Double blind.
Follow-up period:
Thirty six weeks.
Setting:
Forty two sites, USA; April 2001 to November 2004.
Patients:
421 outpatients diagnosed with Alzheimer’s disease (DSM-IV) or probable Alzheimer’s diagnosis (according to history, physical examination, brain imaging, and Mini-Mental State Examination (MMSE) score between 5 and 26), with delusions, hallucinations, aggression, or agitation starting after the onset of dementia, that interfered with functioning, and occurred daily in the last week or intermittently for the last 4 weeks. Exclusions: primary psychotic diagnosis (DSM-IV), delirium, or other dementia; symptoms attributable to substance abuse or disorder other than Alzheimer’s; suicidal; previous treatment with ⩾2 medications tested in this trial; not ambulatory; not living at home or …
Footnotes
For correspondence: Dr Schneider, Keck School of Medicine, University of Southern California, 1510 San Pablo Street, HCC 600, Los Angeles, California 90033, USA; lschneid{at}usc.edu
Source of funding: National Institute of Mental Health, USA.
Footnotes
Please visit http://ebmh.bmj.com/supplemental for reference list.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.